Cancer: The road to amiens

Journal of Clinical Oncology

Volumn 27, Issue 3, 2009, Pages 328-333

  Stewart, David J ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; MITOXANTRONE; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; SORAFENIB; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB;

BREAST CANCER; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG SAFETY; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNITED STATES; UTERINE CERVIX CANCER;

CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; RESEARCH; TREATMENT OUTCOME;

EID: 58549094955     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.9621     Document Type: Review

References (41)

1. Contributors, Wikipedia. Battle of Amiens. Wikipedia, The Free Encyclopedia 2007; http://en.wikipedia.org/w/index.php?title=Battle-of- Amiens&oldid=168905482
2. Contributors. The Battle of Amiens, 8th August 1918: 1918 Australians in France. http://wwwawmgovau/1918/battles/amienshtm
3. Burris HAR, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
4. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 12:356-361, 2007
5. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
6. Cohen MH, Gootenberg J, Keegan P, et al: FDA drug approval summary: Bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713-718, 2007
7. Kane RC, Farrell AT, Saber H, et al: Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278, 2006
8. Cohen MH, Johnson JR, Pazdur R: Food and Drug Administration Drug approval summary: Temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11:6767-6771, 2005
9. Dagher R, Li N, Abraham S, et al: Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147-8151, 2004
10. Brave M, Dagher R, Farrell A, et al: Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology (Williston Park) 20:1401-1410, 2006
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
12. Batalden P, Davidoff F: Teaching quality improvement: The devil is in the details. JAMA 298:1059-1061, 2007
13. Iwata H: Perspective of trastuzumab treatment. Breast Cancer 14:150-155, 2007
14. Khambata-Ford S, Garrett CR, Meropol NJ, et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237, 2007
15. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005
16. Braiteh F, Kurzrock R: Uncommon tumors and exceptional therapies: Paradox or paradigm? Mol Cancer Ther 6:1175-1179, 2007
17. Janne PA, Engelman JA, Johnson BE: Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 23:3227-3234, 2005
18. Contributors, Wikipedia. Oskar von Hutier. Wikipedia, The Free Encyclopedia Aug 28, 2007; http://en.wikipedia.org/w/index.php?title=Oskar-von- Hutier&oldid=154146552
19. Frei III E: Acute leukemia in children: Model for the development of scientific methodology for clinical therapeutic research in cancer. Cancer 53: 2013-2025, 1984
20. Muler JH, Baker L, Zalupski MM: Gastrointestinal stromal tumors: Chemotherapy and imatinib. Curr Oncol Rep 4:499-503, 2002
21. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
22. Perez-Soler R: The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 10:4238s-4240s, 2004
23. Hudis CA: Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51, 2007
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
26. Stewart DJ, Tomiak E, Shamji FM, et al: Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer 44:241-249, 2004
27. Karrison TG, Maitland ML, Stadler WM, et al: Design of phase II cancer trials using a continuous endpoint of change in tumor size: Application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455-1461, 2007
28. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764, 2007
29. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multi-center randomized trial. J Clin Oncol 6:633-641, 1988
30. Bedell CH: A changing paradigm for cancer treatment: The advent of new oral chemotherapy agents. Clin J Oncol Nurs 7:5-9, 2003 (suppl)
31. De Angelis R, Capocaccia R, Hakulinen T, et al: Mixture models for cancer survival analysis: Application to population-based data with covariates. Stat Med 18:441-454, 1999
32. Law NJ, Taylor JM, Sandler H: The joint modeling of a longitudinal disease progression marker and the failure time process in the presence of cure. Biostatistics 3:547-563, 2002
33. Stewart D: Use of semilog plots and nonlinear regression analysis of survival curves to identify prognostically distinct patient subgroups: 18th EORTC-NCI-AACR Symposium. EJC Supplements 4:137, 2006
34. Berton P: Vimy. Toronto, Ontario, McClelland and Stewart Ltd, 1986
35. Humphreys K, Trafton J, Wagner TH: The cost of institutional review board procedures in multicenter observational research. Ann Intern Med 139:77, 2003
36. Koski G: Research ethics and oversight: Revolution, or just going around in circles? The Monitor 21:55-57, 2007
37. Gunsalus CK, Bruner EM, Burbules NC, et al: Mission creep in the IRB world. Science 312:1441, 2006
38. Bennis W: On Becoming a Leader. Reading, MA, Perseus Books, 1994
39. Buckingham M, Coffman C. First, Break All the Rules. New York, NY, Simon & Schuster, 1999
40. Wind J, Main J: Driving Change. New York, NY, Simon & Schuster, 1998
41. Landes D: The Wealth and Poverty of Nations. New York, NY, W.W. Norton & Company, 1999